- Business Model
- B2B
- Website
- cytoreason.com
- Total Funding
- $100.0M
- Last Round
- $80.0M Series BJul 2024
- Rounds
- 3
About
AI-powered drug discovery platform
Summary
CytoReason is an Artificial Intelligence company. It has raised $100.0M in total across 3 rounds, most recently a $80.0M Series B round in Jul 2024. Investors include Pfizer Ventures, Nvidia and Thermo Fisher Scientific.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jul 2024
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
Anthropic is an AI research company that builds reliable, interpretable, and steerable AI systems.
xAI is an AI platform for accelerating human scientific discovery.
Waymo is an autonomous driving technology company with a mission to make it safe and easy for peo...